Clinical Trials Logo

Filter by:
NCT ID: NCT03380338 Completed - Clinical trials for Type 2 Diabetes Mellitus

The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients

Start date: May 11, 2016
Phase: N/A
Study type: Interventional

To investigate whether targeted lifestyle intervention (exercise), induces a change in intestinal fecal microbiota related to improved glycemic control and systemic inflammation in patients with DM type 2.

NCT ID: NCT03380325 Completed - Clinical trials for Diabetes Mellitus, Type 2

The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes

Start date: May 11, 2016
Phase: N/A
Study type: Interventional

This study examines the effects of iloprost - a stable prostacyclin analogue - on insulin-mediated muscle capillary recruitment and whole-body glucose uptake in a cross-over design.

NCT ID: NCT03379909 Recruiting - Bladder Cancer Clinical Trials

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

TROJAN
Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.

NCT ID: NCT03379844 Completed - Clinical trials for Hepatocellular Carcinoma

HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients

Start date: August 21, 2017
Phase: Phase 2
Study type: Interventional

Patients with hepatocellular carcinoma often die from intrahepatic disease since current treatment options are generally limited. Local treatment using holmium radioembolization could offer an effective treatment and a more personal approach than yttrium radioembolization (standard-of-care) as holmium has more imaging options.

NCT ID: NCT03379233 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence

ADVICE
Start date: July 11, 2018
Phase: Phase 3
Study type: Interventional

This study was evaluating the effect of reminder notifications and motivational/adaptive messages on treatment adherence behavior in subjects with COPD. The effect will be measured over 24 weeks on the subject's on time treatment adherence and total treatment adherence. The delivery of the medication and tracking of inhaler use is done by the Concept2 inhaler. The reminder notification, feedback on inhaler use and motivational messages are provided by the patient application, who is receiving the inhaler use information from the Concept2 inhaler.

NCT ID: NCT03378999 Completed - Clinical trials for Cholesterol Metabolism

Rhodospirillum Rubrum and Cholesterol

Start date: June 14, 2018
Phase: N/A
Study type: Interventional

The primary objective of the study is to examine for the first time the LDL cholesterol lowering effect of oven-dried Rhodospirillum rubrum in humans.

NCT ID: NCT03378479 Completed - Clinical trials for Aspergillosis; Pulmonary, Invasive (Etiology)

Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients

POSA-FLU
Start date: December 27, 2017
Phase: Phase 4
Study type: Interventional

The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza. The investigators will perform an interventional non-blinded randomized controlled multicentric proof-of-concept study in patients with severe influenza admitted to the ICU. Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of care) group. Oseltamivir will be started at the discretion of the investigator. Patients in the posaconazole group will receive posaconazole prophylaxis for 7 days. addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU

NCT ID: NCT03377686 Completed - Asthma Clinical Trials

Breath Analysis in Children by New Point-of-care Instruments

Start date: March 2016
Phase: N/A
Study type: Observational

In this study new hand-held devices for measuring exhaled breath will be tested in children with asthma, CF, and healthy controls. Main objectives will be feasibility and discriminative value of these techniques.

NCT ID: NCT03376438 Recruiting - Atrial Flutter Clinical Trials

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

FAST Registry
Start date: June 8, 2017
Phase:
Study type: Observational

The FAST Trial Registry is a prospective observational cohort study of fetuses with a new diagnosis of atrial flutter (AF) or supraventricular tachycardia (SVT) that is severe enough to consider prenatal treatment (see eligibility criteria below). Aims of the Registry include to establish a large clinical database to determine and compare the efficacy and safety of different prenatal treatment strategies including observation without immediate treatment, transplacental antiarrhythmic fetal treatment and direct fetal treatment from the time of tachycardia diagnosis to death, neonatal hospital discharge or to a maximum of 30 days after birth.

NCT ID: NCT03376386 Completed - Clinical trials for Head and Neck Cancer

Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy

ADMIRE
Start date: December 21, 2017
Phase: N/A
Study type: Interventional

Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptive radiotherapy scheme. An FDG-PET/CT scan for re-delineation and re-planning will be made at the end of the second and fourth of week of radiotherapy. The non-responding part of the tumor on FDG-PET will receive a mild dose-escalation. Depending on the metabolic response, the entire tumor will receive 70 Gy or the residual FDG-avid area will receive 74 or 78 Gy.